Understanding how Acinetobacter baumannii responds to stress and antibiotics
Phenylacetic acid catabolism, a novel stress-response pathway in Acinetobacter baumannii
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11076677
This study looks at how a tough bacteria called Acinetobacter baumannii survives even when antibiotics are used, focusing on a special process it uses to stay strong, which could help us find better ways to treat infections for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11076677 on ClinicalTrials.gov |
What this research studies
This research investigates how the bacteria Acinetobacter baumannii, known for causing multidrug-resistant infections, adapts to stressful conditions, particularly in the presence of antibiotics. The study focuses on a specific metabolic pathway involving phenylacetic acid, which helps the bacteria survive and thrive despite antibiotic treatment. By examining how this pathway influences the bacteria's ability to form biofilms and resist treatment, the research aims to uncover new strategies for combating these infections. Patients may benefit from insights that could lead to the development of more effective antimicrobial therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by Acinetobacter baumannii, particularly those with multidrug-resistant strains.
Not a fit: Patients with infections caused by other types of bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively combat multidrug-resistant Acinetobacter baumannii infections.
How similar studies have performed: Other research has shown promise in understanding bacterial stress responses, but this specific pathway involving phenylacetic acid is relatively novel and untested.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FELDMAN, MARIO — WASHINGTON UNIVERSITY
- Study coordinator: FELDMAN, MARIO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acinetobacter Infections